欢迎来到CSNpharm!产品仅用于科研!

400-920-2911 sales@csnpharm.cn

0

Bcr-Abl

Bcr-Abl

货号 产品名 CAS号 信息
CSN15826 ZM 306416 690206-97-4 ZM-306416 is an inhibitor of VEGFR (Flk-1 or KDR) and Flt with IC50 of 100 nM and 2 μM. It also shows inhibition activity against Src and Abl with IC50 values of 0.33μM and 1.3μM, respectively.
CSN28459 SIAIS178 2376047-73-1 SIAIS178 is a potent and selective BCR-ABL degrader based on PROTAC technology with an IC50 of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. SIAIS178 has anticancer activity.
CSN18591 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyrazin-2-yl)pyrimidin-2-yl)amino)benzamide 926037-48-1 Radotinib is a selective BCR-ABL1 inhibitor with IC50 of 34 nM, also inhibits platelet-derived growth factor receptor (PDGFR), is used to treat cancers and Chronic Myeloid Leukemia.
CSN22517 N-Deshydroxyethyl Dasatinib 910297-51-7 PROTAC Bcr-Abl-binding moiety 1 is a Dasatinib-based warhead ligand for conjugation reactions of PROTAC targeting on Bcr-Abl.
CSN23049 PPY-A 875634-01-8 PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinases with IC50s of 9 and 20 nM, respectively.
CSN21067 Ponatinib HCl 1114544-31-8 Ponatinib is a multi-targeted kinase inhibitor with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src respectively.
CSN32501 Vamotinib 1416241-23-0 PF-114 is a Bcr-Abl1 inhbitor.
CSN16663 NVP-BHG 712 940310-85-0 NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition and also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
CSN17632 3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide 1257628-77-5 GZD824 is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl (WT) and Bcr-Abl (T315I) with IC50 of 0.34 and 0.68 nM, respectively.
CSN18803 Olverembatinib dimesylate 1421783-64-3 GZD824 dimesylate is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl (WT) and Bcr-Abl (T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
CSN28520 GMB-805 2489876-41-5 GMB-805 is a novel potent BCR-Abl PROTAC, inducing degradation and demonstrating in vivo activity.
CSN25549 GMB-475 2490599-18-1 GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 reduced viability and increased apoptosis in primary CML CD34+ cells, with no effect on healthy CD34+ cells at identical concentrations.
CSN18538 Flumatinib 895519-90-1 Flumatinib is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively.
CSN16497 N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide 302962-49-8 Dasatinib is a potent and dual Abl/ Src inhibitor IC50 of < 1 nM/0.8 nM respectively and also inhibits c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM.
CSN18475 Dasatinib HCl 854001-07-3 Dasatinib HCl is a potent and dual Abl/ Src inhibitor IC50 of < 1 nM/0.8 nM respectively and also inhibits c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM.
CSN28518 SNIPER(ABL)-039 2222354-29-0 DAS-IAP is a novel PROTAC targeting drug-resistant BCR-ABL.
CSN12423 Danusertib 827318-97-8 Danusertib is a pyrrolo-pyrazole and small molecule Aurora kinases inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively. It is modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc.
CSN27382 CZC-8004 916603-07-1 CZC-8004 is a pan-kinase inhibitor and binds a range of tyrosine kinases, including ABL kinase.
CSN15883 Agerafenib 1188910-76-0 CEP-32496 is an inhibitor of BRAF V600E (IC50 = 14 nM), WT (IC50 = 34 nM) and c-Raf (IC50 = 39 nM). It also exhibits certain inhibitory activity against Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2.
CSN26601 BCR-ABL-IN-3 2240191-12-0 BCR-ABL-IN-3 is a potent and irreversible Bcr-Abl inhibitor with an IC50 of ≤100 nM for Ba/F3Bcr-AblT3151. BCR-ABL-IN-3 has anti-cancer activity[1].
CSN21248 BCR-ABL-IN-1 188260-50-6 BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia.
CSN19269 Bafetinib 859212-16-1 Bafetinib is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit.
CSN18365 AST 487 630124-46-8 AST-487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM. AST487 also inhibits RET,KDR,c-KIT,and c-ABL kinase with IC50 values below 1 μM.
CSN18872 Asciminib 1492952-76-7 Asciminib is a potent and selective allosteric Bcr-Abl inhibitor and inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.
CSN25318 AP23848 834894-21-2 AP23848 is a potent Bcr-Abl inhibitor. In a murine model, AP23848 inhibited activation-loop mutant Kit phosphorylation and tumor growth.
CSN29430 Vodobatinib 1388803-90-4
CSN38604 PD180970 287204-45-9
CSN40473 Herbimycin A 70563-58-5
CSN38802 DB07107 552332-71-5
CSN35035 NVP-BHG712 isomer 2245892-85-5
CSN35548 Dasatinib metabolite M6 910297-53-9
CSN35559 CT-721 1388710-60-8
CSN42896 AZD0424 692054-06-1
CSN66519 Adaphostin 241127-58-2
CSN67518 BCR-ABL1-IN-1 1488090-21-6
CSN68746 PD166326 185039-91-2
CSN79676 CHMFL-ABL-053 1808287-83-3
CSN78338 c-ABL-IN-2 2574593-54-5
CSN78326 c-ABL-IN-3 2626934-64-1
CSN78854 c-ABL-IN-1 2304918-82-7
CSN80455 BP-5-087 1803281-30-2
CSN79422 c-ABL-IN-4 2626934-68-5
CSN83349 Bosutinib hydrate 918639-08-4
CSN84818 Asciminib HCl 2119669-71-3
CSN107180 ON012380 592543-24-3
CSN105890 Tyrphostin AG1112 153150-84-6
CSN107696 Bosutinib isomer 1391063-17-4
CSN107050 ONO12380 936915-58-1
CSN51530 Ruserontinib 1350544-93-2
<< PREV 1 2 NEXT >>
联系
我们